Download Files:
(S)-VQW-765
$100 – $170
Products Details
Product Description
– (S)-VQW-765 ((S)-AQW-051) is an orally active, selective and effective α7 nicotinic ACh receptor (nAChR) partial agonist. (S)-VQW-765 has potential applications in cognitive disorders related to neurological diseases, such as Alzheimer’s disease or schizophrenia[1][2].
Web ID
– HY-19490A
Storage Temperature
– 4°C (Powder, sealed storage, away from moisture)
Shipping
– Room Temperature
Molecular Formula
– C19H22N2O
References
– [1]Feuerbach D, et al. AQW051, a novel, potent and selective α7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation. Br J Pharmacol. 2015 Mar;172(5):1292-304. |[2]Mazurov A, et al. Nicotinic acetylcholine receptor modulators[J]. Small Molecule Therapeutics for Schizophrenia, 2015: 213-253.
Molecular Weight
– 294.39
Compound Purity
– 98.00
SMILES
– CC(C=C1)=CC=C1C2=NC=C(C=C2)O[C@H]3C4CCN(CC4)C3
Clinical Information
– No Development Reported
Research Area
– Neurological Disease
Solubility
– 10 mM in DMSO
Target
– nAChR
Pathway
– Membrane Transporter/Ion Channel;Neuronal Signaling
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
